Rabbit Polyclonal ARL11 Antibody

ARL11 (ADP-ribosylation factor-like protein 11) is a small GTP-binding protein belonging to the ARF/ARL family, which regulates intracellular trafficking, membrane remodeling, and signaling pathways. Initially identified as a tumor suppressor, ARL11 is linked to cancer biology, particularly in leukemia, breast cancer, and prostate cancer, where its downregulation or mutations correlate with disease progression. It also plays roles in cholesterol metabolism, atherosclerosis, and neurodegenerative disorders like Alzheimer’s disease. ARL11 antibodies are essential tools for studying its expression, localization, and function. These antibodies are typically developed using immunogens derived from conserved regions of the human ARL11 protein and validated for specificity via Western blot, immunohistochemistry (IHC), and immunofluorescence (IF). High-quality ARL11 antibodies help detect protein levels in tissue samples, cell lines, or disease models, aiding research on its tumor-suppressive mechanisms, such as interactions with Wnt or p53 pathways. Commercially available antibodies often include knockout-validated options to ensure minimal cross-reactivity. Researchers utilize ARL11 antibodies to explore its role in vesicular transport, apoptosis, and cell cycle regulation, with implications for understanding cancer pathogenesis and developing therapeutic strategies. Recent studies also highlight its potential as a biomarker for early cancer detection or prognosis.